KarMMa-2 Cohort 2c: Efficacy and Safety of Idecabtagene Vicleucel in Patients with Clinical High-Risk Multiple Myeloma Due to Inadequate Response to Frontline Autologous Stem Cell Transplantation

Authors :: Madhav Dhodapkar
Melissa Alsina
Jesus Berdeja
Krina Patel
Ravi Vij
Xavier Leleu
Anna Truppel-Hartmann
Debashree Basudhar
Ethan Thompson
Xirong Zheng
Revathi Ananthakrishnan
Linda Favre-Kontula
Chiara Greggio
Lars Sternas
David Siegel
Source :: Blood. 140:7441-7443
Publication Year :: 2022
Publisher :: American Society of Hematology, 2022.

Full Text Access

Tools